Adaptate is a biotechnology company which spun-out from GammaDelta Therapeutics in 2019. Adaptate is focused on developing therapeutic antibodies to drug targets to modulate the activity of gamma delta T cells. The company has received investment from Abingworth and Takeda Pharmaceutical Company, with support from King’s College London, the Francis Crick Institute and Cancer Research Technology
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $18M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.04.2021 | - | $18M | - |
Mentions in press and media 3
| Date | Title | Description |
| 19.04.2021 | Adaptate Biotherapeutics raises $18 million in Series A2 funding | London, UK... Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited hav... |
| 19.04.2021 | Adaptate Biotherapeutics raises $18 million in Series A2 funding | Adaptate Biotherapeutics raises $18 million in Series A2 funding 19-04-2021 London, UK... Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its ... |
| 19.04.2021 | Seagen gets August PDUFA for Padcev expansions; Adaptate pulls in new cash for gamma delta T cell antibodies | Seagen is riding the wave of two new priority reviews straight to the FDA. The Bothell, WA-based biotech and their partners at Astellas announced Monday that two supplemental BLAs for Padcev had been accepted by US regula... |